Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Tsimberidou on the Next Steps for Personalized Care

July 27th 2011

Dr. Apostolia Tsimberidou from MD Anderson Cancer Center on the Next Steps for Personalized Care

JAK-STAT Signaling Has Many Faces: Inhibitors Offer Hope in Rare Blood Cancers

July 27th 2011

Intense research has resulted in JAK-STAT becoming one of the best-understood signal transduction cascades.

3 Questions for Srdan Verstovsek, MD, PhD

July 26th 2011

Srdan Verstovsek, MD, PhD, is a medical oncologist and associate professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston.

Dr. Kris Discusses the Field of Mutation Testing

July 26th 2011

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center Discusses the Field of Mutation Testing

Dr. Hoos on Why Melanoma is Amenable to Immunotherapy

July 26th 2011

Dr. Axel Hoos medical lead at Bristol-Myers Squibb on Why Melanoma is Amenable to Immunotherapy

Erlotinib Extends PFS in EGFR-Positive Lung Cancer

July 25th 2011

Findings from a randomized phase III trial in China suggest erlotinib is suitable for first-line treatment in patients with EGFR mutation-positive NSCLC.

Ruxolitinib Results Promising in 2 Myelofibrosis Studies

July 25th 2011

Ruxolitinib, an investigational JAK inhibitor, demonstrated significant benefits for patients with myelofibrosis.

Dr. Kris Explains the Use of Gene Signatures

July 25th 2011

Dr. Mark G. Kris from Memorial Sloan-Kettering cancer center Explains How Gene Signatures are Used

Dr. Rini Describes Hypertension as a Biomarker

July 22nd 2011

Dr. Brian I. Rini from the Taussig Cancer Institute Describes Hypertension as a Biomarker in RCC

Dr. West Explains the Pemetrexed Clinical Trial

July 22nd 2011

Dr. Jack West from Swedish Cancer Institute Explains the Pemetrexed Clinical Trial

Dr. Tsimberidou on the Personalized Medicine Results

July 21st 2011

Dr. Apostolia M. Tsimberidou from MD Anderson Cancer Center on the Personalized Medicine Study Results

Karen Hagemaster on Chemo Documentation Study

July 20th 2011

Karen Hagemaster from Advocate Good Samaritan Hospital on Chemotherapy Documentation Study

Dr. Kris Discusses Driver Mutations Test False Negatives

July 20th 2011

Dr. Mark G. Kris thoracic chair at Memorial Sloan-Kettering Cancer Center Discusses Driver Mutations Test False Negatives

Dr. West on the Gefitinib Advanced NSCLC Trial

July 19th 2011

Dr. Jack West Swedish Cancer Institute on the Gefitinib Advanced non-small cell lung cancer Trial

Dr. Hoos Explains the Future of Immunotherapy

July 18th 2011

Dr. Axel Hoos from Bristol-Myers Squibb Explains the Future of Immunotherapy and Ipilimumab's role

Interim Safety Data Compared in Ixabepilone TITAN Trial

July 18th 2011

Researchers are continuing to explore whether ixabepilone (Ixempra) is a better choice as adjuvant chemotherapy for patients with early-stage, triple-negative breast cancer than the standard paclitaxel (Taxol).

Dr. Whelan Provides a MA.20 Trial Result Summary

July 14th 2011

Dr. Tim J. Whelan from Juravinski Cancer Centre Provides a MA.20 Trial Result Summary

Aiming for Immunity: New Therapies in Sights

July 14th 2011

Even before the FDA approved ipilimumab in March, the field of cancer immunotherapy was a lively area of scientific inquiry.

Dr. Hoos Describes Ipilimumab and Future Immunotherapies

July 13th 2011

Dr. Axel Hoos medical lead from Bristol-Myers Squibb Describes Ipilimumab and Future Immunotherapies

Tim Turnham on the Melanoma Research Foundation

July 12th 2011

Dr. Tim Turnham the executive director of the melanoma research foundation Describes the organization